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Abstract: Objective: To investigate whether high-mobility group box-1 induces cell proliferation, invasion and medi-
ates inflammation in ectopic human endometrial stromal cells through Toll-like receptor 4. Methods: Ectopic en-
dometrial specimens were retrieved from patients with ovarian endometrioma having laparoscopy. Ectopic HESCs 
were treated with H2O2 and recombinant HMGB-1 to induce oxidative stress. The effect of oxidative stress on cell 
proliferation and invasion was demonstrated. Receptors for HMGB-1 in NF-κB pathway (TLR4, RAGE), angiogenic 
molecule (VEGF), adhesion molecules (ICAM-1, E-cadherin), and inflammatory cytokines were measured simultane-
ously to the oxidative stress. Results: Ectopic HESCs showed markedly decreased cell viability with the increased 
release of HMGB-1 following treatment with H2O2. When ectopic HESCs were stressed by rHMGB-1, cell proliferation 
and cell migration numbers increased significantly in a dose-dependent manner. Increased TLR4 and RAGE mRNA 
and protein expression levels were noted to rHMGB-1 treatment in a dose-dependent manner. VEGF synthesis was 
also increased by rHMGB-1 treatment. The gene expression of ICAM-1 was upregulated, whereas that of E-cadherin 
was downregulated with rHMGB-1 treatment. Interleukin-6, IL-1β, tumor necrosis factor-alpha, and IL-10 were in-
creased significantly by rHMGB-1 treatment. Inversely, after transfection of small interfering RNA against TLR4, rH-
MGB treatment resulted in decreased cell proliferation and invasion. Conclusion: HMGB-1 activates the NF-κB path-
way via TLR4 to increase cell proliferation, invasion, and the production of various inflammatory markers in HESCs. 
Thus, HMGB-1, TLR4, and NF-κB may represent potential therapeutic targets for the treatment of endometriosis. 
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Introduction
Endometriosis is a chronic, multifactorial dis-
ease that typically develops in women in their 
30 s and 40 s, with negative effects on repro-
ductive function. Since the pathogenesis of 
endometriosis is still unclear and has only been 
hypothesized, current clinical management of 
the condition is limited to conservative treat-
ment such as pain control and fertility treat-
ments as necessary. A study in the early 1990s 
demonstrated increased levels of inflammatory 
cytokines in the peritoneal cavity in endometri-
osis patients [1], suggesting a pathophysiologi-
cal mechanism related to the immune system 
to trigger the establishment of endometriosis. 
Oxidative stress and damage-associated mo- 
lecular pattern (DAMP) are stimuli which leads 
activation of innate immunity, leading to an 
inflammatory response induced by non-infec-
tious cause in humans. High-mobility group 
box-1 (HMGB-1) exists as an intranuclear DNA-
binding protein in mammalian cells, resulting 
in the stabilization of DNA and control of tran-
scriptional activity [2]. Extracellularly released 
HMGB-1 via cell death acts as an endogenous 
ligand activating inflammatory pathways, which 
is known a representative DAMP [3]. We previ-
ously reported the increased release of HMGB-
1 in human endometrial stromal cells (HESCs) 
by oxidative stress-induced cell death. Recom- 
binant HMGB-1 (rHMGB-1) treatment to HESCs 
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showed a dose-dependent correlation with 
expression of its receptor Toll-like receptor 4 
(TLR4), and changes were consistently corre-
lated according to TLR4 antagonist and nu- 
clear factor-kappa B (NF-κB) inhibitor treatment 
doses. Thus, the innate immune response via 
HMGB-1 and TLR4/NF-κB was suggested as a 
possible mechanism contributing to the devel-
opment of endometriosis by inducing altera-
tions in the naïve, eutopic endometrium. Accor- 
dingly, we hypothesized that HMGB-1 may play 
an important role in the early development of 
endometriosis. 
To test this hypothesis, in the present study, 
we sought to elucidate whether HMGB-1 could 
induce the proliferation and invasion, and medi-
ate inflammation in ectopic HESCs in vitro via 
TLR4, contributing to the progression of endo-
metriosis. In addition to helping to elucidate 
the detailed pathogenic mechanism, these 




From October 2014 to March 2015, ectopic 
endometrial specimens were obtained from 10 
patients who were surgically diagnosed endo-
metriosis. The ectopic endometrium was col-
lected from the endometrioma of the ovary. All 
10 patients were of reproductive age and none 
had had hormonal medication for at least 3 
months preoperatively. The study was approved 
by the institutional review board of Severance 
Hospital, Yonsei University College of Medicine 
(4-2014-0560). All participants have been pro-
vided written consent after agreement.
Sample collection 
After the endometriotic cyst was enucleated, a 
1.0 × 1.0 × 1.0-cm3 section was sampled at the 
cyst wall. Each specimen was placed in a buff-
ered saline solution after extraction and sent to 
the laboratory, right after.
Cell culture
Isolated ectopic HESCs were cultured as de- 
scribed previously [4]. After washing and sec-
tioning in phosphate-buffered saline, the cells 
were treated with 0.25% trypsin/ethylenediami-
netetraacetic acid (Gibco, Invitrogen) at 37°C 
for 30 min. During incubation, the cells were 
tapped every 5 min to enhance detachment. 
Supernatant was isolated and then ectopic 
HESCs were unfolded in Dulbecco’s modified 
Eagle’s medium/F12 (DMEM/F12, HyClone, 
Logan, UT, USA) with 10% fetal bovine serum 
(FBS; Gibco, Invitrogen). The stromal-enriched 
fraction was cultured in 75-mL culture flasks at 
37°C, in humidified atmosphere of 95% air and 
5% CO2. Passage 2-6 HESCs were used in the 
experiments. 
Cell treatment and & study design
To induce oxidative stress in ectopic HESCs, 
the endometrial cells were incubated with 0, 
0.01, 0.1 or 1 nM H2O2 for 48 h. H2O2 was us- 
ed to induce passive release of extracellular 
HMGB-1 resulted from cell necrosis. To confirm 
oxidative stress-induced necrosis, the cell pro-
liferation of ectopic HESCs and passive HMGB-
1 release were examined with an MTT assay. 
To evaluate the influence of DAMP on ectopic 
HESCs, they were incubated with 0, 5, and 10 
μM recombinant HMGB-1 (rHMGB-1; Sino, 
Beijing, China) for 48 h. TLR4, receptor for 
advanced glycation end products (RAGE), and 
vessel endothelial growth factor (VEGF) were 
examined for mRNA and protein expression. 
Likewise, mRNA expression levels for intracel-
lular adhesion molecule-1 (ICAM-1) and E-cad- 
herin, and for inflammatory cytokines were 
measured after 48 hr of rHMGB-1 treatment. 
Further, TLR4 was inhibited by transfection of 
small interfering RNA (siRNA) and treated with 
rHMGB-1 thereafter; the cell migration was 
evaluated to examine the changes in cell 
invasion. 
Cell proliferation assays (CCK-8)
In 6-well tissue culture plates, ectopic HESCs 
were seeded at a density of 1 × 105 cells/well. 
After 24 h, the culture medium was exchanged 
to DMEM/F12 with 2% FBS. followed by treat-
ment with 0, 0.01, 0.1, or 1 nM H2O2 for 48 h to 
induce oxidative stress. To confirm oxidative 
stress-induced necrosis, cell proliferation as- 
says were performed by dropping 100 μL of 
Cell Counting Kit-8 (CCK-8; Dojindo, Japan) into 
each well, and incubating at 37°C for 1 h. The 
supernatants were then plated to 96-well and 
measured at an optical density (OD) of 450 nm 
using a VersaMax reader (Molecular Devices, 
Sunnyvale, CA, USA).
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Examination of HMGB-1 release following cell 
death
To measure the amount of passive HMGB-1 
released following cell death, 3 × 105 HESCs 
were seeded in 6-well plates and incubated at 
37°C. After 24 h, the medium was changed to 
serum-free DMEM/F12. HESCs were incubated 
for 1 h with 0, 50, or 100 μM H2O2 and then 
with 100 μL of MTT solution (Sigma), which 
were incubated at 37°C in a 5% CO2 incubator 
for 4 h further. After removal of the medium, 
each well was treated with 500 μL dimethyl 
sulfoxide (DMSO; Sigma), and incubated on a 
shaker for 10 min. Lastly, the OD was measured 
with a VersaMax reader at 562 nm to deter-
mine the cell viability rates. The supernatants 
were harvested for subsequent western blot-
ting to examine the extent of HMGB-1 release. 
siRNA transfection
siTLR4 RNA was purchased from Thermo Fisher 
Scientific (CA, USA). HESCs were transfected 
with siRNA oligonucleotides using Lipofectamine 
RNAiMAX (Thermo Fisher Scientific, CA, USA) 
according to the manufacturer’s instruction. 
After 6 h, the cells were washed and incubated 
overnight in complete medium. 
Cell invasion and migration assay
Transwell matrigel invasion chambers (Corning 
Inc., Lowell, MA, USA) were used for migration 
and invasion assays. After 24 h post-transfec-
tion, cells were spreaded to a single cell sus-
pension, washed in PBS and resuspended in 
DMEM/F12 without FBS. For the migration 
assay, 2 × 105 cells in 100 μL DMEM/F12 with-
out FBS were seeded in the upper chamber of 
24-well plate. The lower chamber was filled with 
DMEM supplemented with 20% FBS and 0, 5, 
and 10 ng/mL of rHMGB-1. Cells were cultured 
in standard condition. After 48 h, cells on the 
upper surface of the plate were removed by 
wiping with a wet cotton swab and washed in 
PBS several times. The migrated cells on the 
lower surface of the upper chamber were fixed 
in methanol for 10 minutes, dried at room tem-
perature, stained with Diff-Quik solution. The 
migrated cells were counted, and photograph- 
ed under a Carl Zeiss microscope (LSM 710, 
Germany). Examinations were performed 3 
rounds totally, and the cells in five random 
fields on each well were chosen for count. For 
the invasion assay, 5 × 104 ectopic HESCs were 
seeded onto the upper matrigel chamber with 
serum-free DMEM. After 48 h, the cells that 
invaded the lower surface were collected, 
stained, and then counted under the micro-
scope (LSM 710, Carl Zeiss, Germany). 
Real-time reverse transcription-polymerase 
chain reaction (RT-PCR)
Cell-free total RNA was pulled out from the 
cell lysates with a RNeasy kit (Qiagen, Hilden, 
Germany). cDNA was produced with an oligo-dT 
primers (Invitrogen) using 1 μg of total RNA. 
RT-PCR for TLR4, vascular endothelial growth 
factor (VEGF), and E-cadherin with ABI Step- 
OnePlus system (Applied Biosystems, Foster 
City, CA, USA) and SYBR green RT-PCR master 
mix (Toyobo, Osaka, Japan) was utilized for 
each. The primers used were TLR4, 5’-CAGA- 
GTTTCCTGCAATGGATCA-3’ and 5’-GCTTATCTG- 
AAGGTGTTGCACAT-3’; VEGF, 5’-GGA GGAGGG- 
CAGAATCATCAC-3’ and 5’-ATTGGATGGCAGTAG- 
CTGCCT-3’; E-Cadherin, 5’-TCATGAGTGTCCCCC- 
GGTAT-3’ and 5’-TCTTGAAGCGATTGCCCCAT-3’; 
ICAM-1, 5’-TCT TCC TCG GCC TTC CCA TA-3’ and 
5’-AGG TAC CAT GGC CCC AAA TG-3’. Glyceral- 
dehyde-3-phosphate dehydrogenase (GAPDH) 
5’-TCGACAGTCAGCCGCATCTTCTTT-3’ and 5’-AC- 
CAAATCCGTTGACTCCGACCTT-3’ was used as 
endogenous reference gene. The PCR condi-
tions were 10 min at 95°C, 15 sec at 95°C, 1 
min at 6°C, and 15 sec at 9°C, repeated 40 
times in a row. The data were corrected for 
GAPDH expression and the PCR results were 
extended to a 1.5% agarose gel containing 
tidum for bromide and quantified by Image J 
(National Institute of Health).
Western blotting 
Cell lysis was induced in a radioimmunopreci- 
pitation analysis buffer (RIPA buffer; Intron, 
iNtRON Biotechnology, Seongnam, Korea) with 
protease inhibitor cocktail (Cell Signaling Te- 
chnology, Beverly, MA, USA). Subsequently, 
after mixing the lysed cells, 40 μL was distrib-
uted in each. Then the divided cells were col-
lected, centrifuged at 4°C for 30 min at 13,000 
rpm, and the amount of protein in the super- 
natant was quantified with a BCA protein analy-
sis kit (Thermo Scientific, Hudson, NH, USA). 
Western blotting was carried out in the follow-
ing order. 30 micrograms of each lysate were 
placed in 5X buffer and boiled. The centrifuged 
supernatant was filtered through sodium do- 
decyl sulfate-polyacrylamide gel electrophore-
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sis (SDS-PAGE) on an 8% gel and then moved to 
polyvinylidene fluoride membranes (Millipore, 
Eschborn, Germany). BSA treatment was then 
performed at room temperature for 1 hour and 
the membranes were each cultured overnight 
at 4°C with the primary antibody. The antibod-
ies used were TLR4 (polyclonal anti-rabbit, 0.3 
μg/mL; GeneTex, Irvine, CA, USA), VEGF (poly-
clonal anti-rabbit, 1 μg/mL; Abcam, Cambrid- 
ge, UK), E-Cadherin (Monocle, private section-
-Rabbit; Cell Signaling Technology, Beverly, 
MA, USA) and GAPDH (monoclonal antibody-
-mouse, 0.1 μg/mL; Millipore). Secondary anti-
bodies include anti-mouse antibody (IgG, 0.27 
μg/mL; Jackson, West Grove, PA, USA) and 
anti-rabbit antibody (IgG, 0.27 μg/mL; Jackson) 
bound to horseradish peroxidase were used. 
Using enhanced chemiluminescence solution 
(Advansta, San Francisco, CA, USA), bands 
To present extracellular release of HMGB-1 
caused by necrosis, ectopic HESCs were treat-
ed with H2O2. We intended to induce sustain- 
ed oxidative stress by increasing extracellular 
HMGB-1. There was a gradual increase in ecto-
pic HESC proliferation with increasing concen-
tration of H2O2 to induce oxidative stress (Figure 
1A). The MTT assay results showed that cell 
death was significantly induced with increasing 
H2O2 concentration (Figure 1B), and HMGB-1 
release was increased due to cell death (Figure 
1C). 
Changes in ectopic HESCs after rHMGB-1 
treatment 
After H2O2, the cells were treated with rHMGB-
1. The experiment was conducted to mimic the 
environment wherein passive release of HMGB-
Figure 1. Cell changes and passive release of HMGB-1 after inducing necro-
sis by H2O2 treatment in ectopic HESCs. Oxidative stress caused cell prolif-
eration, although not statistically significant (A), decrease of cell viability (B), 
and increase of HMGB-1 release (C) in ectopic HESCs. *P < 0.05 compared 
to 0 μM H2O2 treatment. 
#P < 0.05 compared to 50 μM H2O2 treatment.




After ectopic HESC treatment 
with 0, 5, and 10 ng/mL rH- 
MGB-1 for 48 h, the superna-
tant was collected. Superna- 
tants was analyzed for inter-
leukin (IL)-6 (BD bioscience, 
San Jose, CA, USA), tumor 
necrosis factor (TNF)-α (GE 
healthcare, Buckinghamshire, 
UK), IL-1β (Abcam, Cambridge, 
UK), and IL-10 (Abcam, Cam- 
bridge, UK) using respective 
ELISA kits. The OD was mea-
sured at 450 nm.
Statistical analysis 
Kruskal-Wallis tests with Du- 
nn’s procedure was perform- 
ed to determine the differenc-
es in the levels of mRNA and 
protein. SPSS 23.0 (IBM, NY, 
USA) was used. P values of 
less than 0.05 were consid-
ered showing difference with 
significance, statistically.
Results
Cell proliferation and HMGB-
1 release after H2O2 treat-
ment
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1 increases due to oxidative stress-induced cell 
death. Cell proliferation and invasion increased 
after rHMGB-1 treatment in a dose- and time-
dependent manner (Figure 2A, 2B). Moreover, 
with increasing rHMGB-1 dosage, the expres-
sion of TLR4 and RAGE showed a marked 
increase at the mRNA (data not shown) and 
protein (Figure 3) levels. 
Changes of adhesion and angiogenic factors 
after rHMGB-1 treatment 
After applying rHMGB-1 at different doses for 
48 h, expression of the angiogenic marker 
VEGF markedly increased at the mRNA and pro-
tein levels (Figure 4A, 4B). The mRNA level of 
another angiogenic marker, ICAM-1, also signi- 
ficantly increased at 10 ng/mL treatment of 
rHMGB-1 compared to the naïve control group 
(Figure 4A). By contrast, expression of the 
adhesion marker E-cadherin was significantly 
inhibited with rHMGB-1 treatment (Figure 4A). 
Inflammatory cytokine secretion in the HESC 
supernatant after rHMGB-1 treatment
After applying oxidative stress with rHMGB-1 
at different doses for 48 h, the levels of in- 
flammatory cytokines IL-6 and IL-10 significant-
ly increased in the supernatants of the HESCs 
in a dose-dependent manner, and the levels of 
TNF-α and IL-1β increased significantly at the 
higher dose of rHMGB-1 (Figure 5).
Cell invasion after TLR4 inhibition 
To examine signal transduction via TLR4 in 
inflammatory pathway in HESC, TLR4 was sup-
Figure 2. Increased cell proliferation and migration after rHMGB-1 treatment. Cell proliferation (A) and invasion 
assay (B) after inducing oxidative stress in ectopic HESCs with rHMGB-1 treatment. The migrating cell number 
was significantly increased in each culture group: 24 h, 48 h, 72 h compared between 0 ng/mL and 10 ng/mL of 
rHMGB-1 treatment. Treatment with 5 ng/mL, in contrast to 0 ng/mL of rHMGB-1, led to an increased migration of 
cells, however, the difference was not statistically significant. *P < 0.05 compared to 0 ng/mL rHMGB-1 treatment; 
#P < 0.05 compared to 5 ng/mL rHMGB-1 treatment.
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pressed by transfection of small interfering 
RNA (siRNA) targeting TLR4 (siTLR4) and the 
cells were treated with different doses of 
rHMGB-1. Suppression of TLR4 led to signifi-
cant decrease of HESC migration (Figure 6). 
Discussion
In the present study, we obtained evidence for 
scheme of inflammatory pathway activated via 
TLR4 in ectopic HESC. The endogenous danger 
Figure 3. RAGE and TLR4 mRNA and protein expression after rHMGB-1 treatment. Protein expression levels of the 
receptors, RAGE and TLR4 were significantly increased after HMGB-1 treatment for 48 h in a dose-dependent man-
ner.
Figure 4. mRNA expression of VEGF, ICAM-1 and E-Cadherin (A) after treatment with rHMGB-1 by dosage (48 h) 
and protein expression of VEGF (B). (A) VEGF mRNA expression was increased significantly according to the dose 
increase of rHMGB-1. ICAM-1 mRNA expression was increased only at 10 ng/mL of rHMGB-1, whereas E-Cadherin 
showed a significant decrease by rHMGB-1 treatment in a dose-dependent manner. (B) VEGF protein synthesis 
was significantly increased by rHMGB-1 treatment; however, there was no differences between rHMGB-1 treatment 
doses. *P < 0.05 compared to 0 ng/mL rHMGB-1 treatment.
HMGB-1 mediates inflammation in endometriosis
1406 Am J Transl Res 2021;13(3):1400-1410
signal HMGB-1 released after cell death in- 
duced cell proliferation, increased expression 
of angiogenesis, adhesion and inflammation 
via TLR4. In our previous study [5], we demon-
strated a scheme of altered human eutopic 
endometrial stromal cell by HMGB-1, suggest-
ing initiation of inflammation by oxidative 
stress. Extracellular release of HMGB-1 from 
eutopic endometrial stromal cell induced by 
H2O2 was confirmed by RT-PCR and western 
blot. In the current study, we tried to demon-
strate TLR4-mediated mechanism of inflamma-
tion induced by HMGB-1 in already altered 
endometrial stromal cells (ectopic HESC). HM- 
GB-1 increased TLR4 expression in ectopic 
HESC, which showed a cascade of increased 
angiogenesis, adhesion, and inflammation pro- 
bably due to activation of the NF-κB signaling 
pathway [6]. Inversely, after inhibiting TLR4 by 
siRNA transfection, cell proliferation and migra-
tion significantly decreased, further suggesting 
that the DAMP exerts its actions via TLR4 in 
ectopic HESCs. 
As a possible trigger that activates the NF-κB 
pathway, chronic inflammation related to in- 
nate immunity has been suggested to play a 
pathophysiological role in endometriosis devel-
opment [7]. NF-κB has been extensively stud-
ied in the field of endometriosis research [8, 9], 
as well as in other inflammation-related diseas-
es [10]. NF-κB mediates the induction of pro-
inflammatory genes, including cytokines, che-
mokines, and other inflammatory mediators, in 
various immune cells such as macrophages, 
dendritic cells, and T and B lymphocytes. In 
endometriosis, an inflammatory signature rep-
resenting a shift toward a relative dominance 
of Th2-type cytokines from Th1 dominant cell 
population has been suggested [11], and aber-
rantly regulated immune factors have been 
found, such as increased cytokines (TNF-α, 
IL-1β, IL-8, IL-6, IL-10) [12-14] and decreased 
natural killer cells in the peritoneal fluid [15]. 
Accordingly, there has been extensive research 
devoted to the role of the NF-κB pathway in 
endometriosis, with some investigations reveal-
Figure 5. Cytokine secretion in ectopic HESCs after rHMGB-1 treatment. Secretion of pro-inflammatory cytokines 
including IL-6, TNF-α and IL-1β by ectopic HESCs was significantly increased with increased doses of rHMGB-1. 
Secretion of anti-inflammatory cytokine IL-6 was increased in a dose-dependent manner. *P < 0.05 compared to 0 
ng/mL rHMGB-1 treatment.
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Figure 6. Cell invasion and migration assay after treating rHMGB-1 to siTLR4-transfected HESCs. Cell invasion (A), migration (B) were significantly decreased with 
treatment of 5 ng/mL and 10 ng/mL rHMGB-1 in siTLR4-transfected HESCs compared to the untreated control. *P < 0.05 compared to 0 ng/mL rHMGB-1 treat-
ment.
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ing increased expression of NF-κB subunits in 
the endometrium [8, 16] and its activation in 
macrophages [17]. In addition to endometrio-
sis, the NF-κB pathway has been widely impli-
cated in carcinogenesis, autoimmune diseas-
es, and inflammatory diseases, and these stud-
ies have provided clues into the possible sti- 
muli that could activate the NF-κB pathway in 
endometriosis.
Stimuli such as hypoxia, oxidative stress, DAMP, 
microbium, iron burden, inflammasomes, and 
cytokines have been suggested to lead to NF- 
κB pathway activation, resulting in an increase 
of cell proliferation, decreased apoptosis, and 
inflammation modulation [7, 9, 18, 19]. In the 
present study, we focused on the potential role 
of innate immunity involving DAMP and the 
NF-κB pathway in endometriosis. Previous stud-
ies demonstrated different proliferation, decid-
ualization, and survival rates of stromal cells 
isolated from the eutopic endometrium, ovari-
an endometrioma, and deep-infiltrating endo-
metriosis tissues, suggesting that different ori-
gins may reflect their different characteristics 
in endometriosis [20, 21]. Here, we demon-
strated eutopic endometrial stromal cells as a 
naïve cell type before the pathologic modifica-
tions occurring in endometriosis, and ectopic 
endometrial stromal cells as a post-modified 
cell due to pathologic changes. In our study, we 
demonstrated a possible mechanism regarding 
oxidative stress and HMGB-1 providing vis-
cious, endogenous stimuli for chronic inflam-
mation in pelvic cavity. Oxidative stress and 
HMGB-1 showed altering ability in eutopic en- 
dometrium, which leaded changes closer to 
ectopic endometrium in our previous work [5]. 
Serially, in current study, the danger signal has 
shown aggravating cell invasion, proliferation 
and changes of molecular level in ectopic 
HESCs. We suggest that oxidative stress and 
HMGB-1 may affect progression of endometrio-
sis, not only initiation of the pathologic changes 
in eutopic endometrial cells. 
HMGB-1 is stored in the nucleus where it acts 
as a DNA-binding protein that participates in 
DNA replication, recombination, transcription, 
and repair [3, 22]. However, when HMGB-1 is 
released for any reason, extracellular HMGB-1 
functions as a signaling molecule in the inflam-
mation pathway, immune system, and tissue 
regeneration, including in cell differentiation 
and migration [2]. Extracellular HMGB-1 can be 
actively secreted by inflammatory cells stimu-
lated by DAMP, cytokines, or chemokines, or 
can be passively released by dead, dying, or 
injured cells with several different mechanisms 
proposed [23]. Extracellular HMGB-1 acts as 
a DAMP molecule, and its activity depends on 
the redox state, receptors, and their interactive 
partners. HMGB-1 has been suggested as a 
key molecule inducing chronic inflammatory 
processes in rheumatic arthritis [24], retinopa-
thy [25], sepsis [26], atherosclerosis [27, 28], 
and liver diseases [23]. In particular, athero-
sclerosis and liver disease have another com-
mon feature with endometriosis in causing an 
increase of stromal fibrosis besides chronic 
inflammation. For example, a “two-hit” hypoth-
esis has been proposed to explain the patho-
genesis of non-alcoholic fatty liver disease 
(NAFLD) [29]. When the liver becomes sensi-
tized to the injuries caused by steatosis, sec-
ond hits by cytokines, chemokines, and oxida-
tive stress result in de novo lipogenesis and 
increased lipid deposition in the liver. HMGB-1-
TLR4-MyD88 signaling has been considered to 
be an important key mechanism in the early 
stage of progression to NAFLD [30]. In NAFLD, 
the HMGB-1 released by injured hepatocytes 
activates the NF-κB pathway via TLR4 and 
MyD88, leading to hepatic stellate cell activa-
tion and the increased expression and synthe-
sis of alpha-smooth muscle actin and collagen, 
which collectively result in liver fibrosis [23]. 
Accordingly, our results suggest a similar patho-
genic mechanism of endometriosis given the 
possible passive release and active secretion 
of HMGB-1 from ectopic endometriotic cells, 
which may activate the NF-κB pathway via 
TLR4. Activation of NF-κB resulted in decreased 
expression of E-cadherin, and increased ex- 
pression of ICAM-1 and VEGF, along with the 
secretion of concomitant proinflammatory (IL-6, 
TNF-α, and IL-1β) and anti-inflammatory (IL-10) 
cytokines. The increased expression levels of 
VEGF [31], ICAM-1 [32], and cytokines is in line 
with previous results. The adhesion marker 
E-cadherin is important for maintaining cell-to-
cell adhesion and cell polarity, and decreased 
expression of E-cadherin has been reported in 
various stages of endometriosis [33]. 
Our study has a limitation in that these findings 
are based only on in vitro experiments. Surely, 
suggested role of the HMGB-1-TLR4-NF-κB axis 
in early endometriosis development needs to 
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be evaluated and validated through in vivo 
experiments. However, endometrial stromal 
cells have been suggested to reflect specific 
characteristics of ectopic endometrial cells [6]. 
Since endometriotic tissue is composed of 
glands, extracellular matrix and stroma mainly, 
many studies applied the stromal cells as a 
representative in vitro model to assess treat-
ment of endometriosis [34]. Another possible 
limitation is the knockdown with siRNA for 
TLR4. Although siRNA transfection is a popu-
larly used method in endometrial cell experi-
ments, there may exist an off-target signature 
on an unexpected target of the pathway. Ne- 
vertheless, the aim of these experiments was 
to demonstrate a pathway stimulated by TLR4, 
and the results were consistent in terms of the 
changes observed pre- and post-downregula-
tion. However, our study has the main advan-
tage in terms of a rare serial demonstration of 
a possible pathogenic mechanism in endome-
triosis. Specifically, our results suggest that 
HMGB-1 via TLR4 may activate the NF-κB path-
way to result in inflammatory changes in ecto-
pic HESCs. Thus, the innate immune response 
may play an important role in the development 
of endometriosis, suggesting new targets for 
research and treatment.
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